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BACKGROUND: Several studies have suggested a protective effect of folic acid (FA) on congenital heart anoma-
lies. Down syndrome (DS) infants are known to have a high frequency of heart anomalies. Not all children with
DS suffer from heart anomalies, which raises the question whether maternal factors might affect the risk of these
anomalies. Our objectives were to investigate whether ﬁrst-trimester FA use protects against heart anomalies
among DS children. METHODS: Women with liveborn DS children participating in the Slone Epidemiology
Center Birth Defects Study between 1976 and 1997 were included. We performed case-control analyses using
DS, with heart anomalies as cases and DS, without heart anomalies as controls. Subanalyses were performed
for defects that have been associated with FA in non-DS populations (conotruncal, ventricular septal [VSD])
and for those that are associated with DS (ostium secundum type atrial septal defects [ASD] and endocardial
cushion defects [ECD]). Exposure was deﬁned as the use of any FA-containing product for an average of at
least 4 days per week during the ﬁrst 12 weeks of pregnancy, whereas no exposure was deﬁned as no use of
FA in these 12 weeks. RESULTS: Of the 223 cases, 110 (49%) were exposed versus 84 (46%) of the 184 controls.
After adjustment for possible confounders, no protective effect of FA was found on heart anomalies overall
(OR 0.95, 95% CI: 0.61–1.47) nor separately for conotruncal defects, VSDs, ASDs, or ECDs. CONCLUSIONS:
Our study does not show a protective effect of FA on heart anomalies among infants with DS. Birth Defects
Research (Part A) 76:714–717, 2006.  2006 Wiley-Liss, Inc.
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INTRODUCTION
Although clinical features of Down syndrome (DS) are
well recognized, it remains unclear how the extra chromo-
some relates to the high incidence of certain major malfor-
mations among DS children compared to the unaffected
population. For example, cardiac malformations are com-
monly seen among DS infants, with incidence rates varying
between 40 and 50%. Shapiro (1983) suggests that besides
direct effects of the chromosomal abnormality, it might be
possible that maternal risk factors interact with an already
susceptible genotype, leading to the development of major
anomalies in some individuals but not in others.
Studies on maternal risk factors and major birth defects
restricted to infants with DS are few and results are not
consistent, but there is some evidence that environmental
factors might inﬂuence the occurrence of defects among
fetuses with an extra chromosome 21. For maternal age,
ﬁndings differ on the direction of risks: while Ka¨lle`n et al.
(1996) found that DS infants born to teenage mothers had
a decreased risk for cardiac defects, which was particu-
larly pronounced for endocardial cushion defects (ECDs)
and ventricular septum defects (VSDs), they also found an
increased risk for megacolon for mothers <25 years of
age. Khoury and Erickson (1992) also found an inverse
association, but with maternal age and oral clefts; addi-
tionally, they found an association between maternal race
and cardiac defects (40% among blacks vs. 17% in whites).
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With respect to exogenous factors, Fixler and Threlkeld
(1998) found no differences in risk of heart defects in rela-
tion to maternal illness, medication use, or consumption of
caffeinated beverages, cigarettes, or alcohol, but others did
ﬁnd an effect of such maternal exogenous exposures.
Khoury and Erickson (1992) found an association between
ﬁrst-trimester fever and duodenal atresia. Although this
was not conﬁrmed in a later study by Torfs and Christian-
son (1999), the latter did ﬁnd associations between coffee
consumption and maternal fever and Hirschsprung’s dis-
ease as well as between smoking and cardiac defects; alco-
hol was not associated with any defect. Taken together,
these studies suggest maternal factors might play a role in
the origin of major congenital anomalies among infants
with DS.
No study, however, has evaluated the risks of major
birth defects among DS affected infants in relation to
maternal use of folic acid (FA). In the general population,
studies suggest that FA use may reduce the risk of cardiac
defects. While Werler et al. (1999) found no association
between multivitamin use and conotruncal defects or
VSDs, other studies did ﬁnd evidence of such an associa-
tion. In a randomized clinical trial, Czeizel (1998) found a
signiﬁcant protective effect of FA-containing multivitamins
for heart defects overall (odds ratio [OR] 0.42, 95% conﬁ-
dence interval [CI] 0.19–0.98) and for conotruncal defects
[OR] 0.29, 95% CI 0.09–.097) in particular. A number of
observational studies were consistent with that ﬁnding. For
example, Botto et al. (2000) found signiﬁcant protective
effects of multivitamins (which usually contain FA) on out-
ﬂow tract defects, VSDs, and cardiac defects overall. Fur-
thermore, studies of Hernandez-Diaz et al. (2000) and
Meijer et al. (2005) provide indirect evidence of a possible
protective effect of FA on cardiac defects. Both found an
increased risk of cardiac defects after intrauterine exposure
to medications that antagonize the effects of FA; this risk
diminished if FA supplements were taken along with the
FA antagonists (Hernandez-Diaz et al., 2000). Although
these studies did not investigate the effect on heart anoma-
lies speciﬁcally among DS affected infants, their results
raise the question of whether FA might reduce the risk of
heart anomalies in this particular population. We therefore
sought to evaluate the hypothesis that FA has a protective
effect on heart anomalies among infants with DS.
MATERIALS AND METHODS
Since 1976, the Boston University Slone Epidemiology
Center Birth Defects Study (BDS) has been interviewing
mothers of children with a range of birth defects (Mitchell
et al., 1981). Until 1997, mothers from the areas around Bos-
ton (since 1976), Philadelphia (since 1977), and Toronto
(since 1978) were interviewed in person, within 6 months
of delivery, usually in the subject’s home, by a trained
study nurse. Because of personnel limitations, not all eligi-
ble subjects were approached for interview. Rather, those
subjects that were approached were selected based on ‘‘pri-
ority’’ diagnoses that reﬂected changing research interests
of the program. For example, from 1983 to 1987 DS was on
the priority list but neural tube defects (NTDs) were not.
From 1988 to 1992, NTDs were on the priority list, but DS
was not. Therefore, during the latter period, all subjects
with an NTD and only a sample of those with DS were
approached for interview. However, selection of subjects
for interview was never dependent on exposure to any par-
ticular agent. The interview contained questions about de-
mographic, reproductive, and medical factors, as well as
details about all medications used, including vitamins. The
product name, starting and stopping dates, and frequency
of use were recorded for each vitamin product taken be-
tween 2 months before through the end of pregnancy.
The present analyses include data on liveborn infants
with DS enrolled between 1976, the start of the study, and
1997, the year before food fortiﬁcation with FA. We ex-
cluded infants with gestational age <37 weeks whose only
cardiac anomaly was patent foramen ovale, ostium secun-
dum type atrial septal defects (ASD), or patent ductus arte-
riosus (n ¼ 15). Among the remaining 773 DS infants, cases
were deﬁned as infants with any heart anomaly. Separate
analyses were performed for conotruncal defects, VSDs,
ECDs, and ASDs. The ﬁrst 2 defects were included because
of the inverse association with FA in the literature and the
latter 2 because they are commonly seen among DS infants.
The four groups were not mutually exclusive. Controls
were DS infants without a heart anomaly.
Since lunar months 2 and 3 are most important regard-
ing development of heart anomalies, exposure to FA was
deﬁned as the use of any FA-containing product for at least
48 days during the ﬁrst 12 weeks of pregnancy (lunar
months 1–3), which corresponds to an average of 4 days
per week during this period. In all exposed study subjects,
the exposure occurred on 16 days in lunar months 2 and
3. No exposure was deﬁned as no FA use at all in these ﬁrst
12 weeks of pregnancy.
Multivariate models were used to calculate adjusted
ORs and 95% CIs. Variables that were related to exposure
and/or outcome were included in the model: maternal
race (white/nonwhite), maternal age (<25, 25–29, 30–34,
and >34), maternal education (<12, 12, 13–15, and >15
years), maternal diabetes (yes/no), year of birth (<83, 83–
87, 88–92, and >92), and geographic center (Boston, Phila-
delphia, and Toronto).
RESULTS
Of the 773 DS affected infants in the database, 366 were
excluded because the mothers used FA but at frequencies
and durations that were inadequate to meet the exposure
criteria. Among the 407 who met these criteria, 223 (55%)
were cases and 184 (45%) were controls. The cases included
20 births with conotruncal defects, 73 with VSD, 73 with
ASD, and 85 with ECD. Among the excluded births, a simi-
lar distribution of cases and controls was found (58%
cases).
The characteristics of the cases and controls are shown in
Table 1. Among cases, more mothers reported never hav-
ing smoked and more had diabetes, whereas fewer moth-
ers were White and fewer infants were male (all P < .05).
There was little difference between cases and controls for
maternal age, education, parity, alcohol drinking, or
whether the pregnancy was planned.
Of the 223 cases, 110 (49%) were exposed to FA, versus 84
(46%) of the 184 controls. Logistic regression that adjusted
for race, maternal age, maternal education, maternal diabe-
tes, year of birth, and center of birth revealed no protective
effect of FA for heart anomalies overall (OR 0.95, 95% CI
0.61–1.47), as is shown in Table 2. Maternal FA use was also
not associated with any of the 4 cardiac subgroups; ORs
showed some variation, but none of the CIs excluded 1.0.
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DISCUSSION
In this study, we examined whether the risk of congeni-
tal heart defects among DS affected infants is decreased
by ﬁrst trimester FA exposure. The literature provides
some support for such an effect in the general population,
particularly with respect to conotruncal defects and VSDs.
However, the present data do not provide evidence for a
protective effect of FA on the occurrence of heart anoma-
lies overall among DS affected infants, nor for the sub-
groups of conotruncal defects, VSDs, ASDs, or ECDs.
The strength of this study is that we only included chil-
dren born to mothers who took FA regularly or did not
take FA at all. By eliminating occasional FA users, our ap-
proach maximized the opportunity to identify a protective
effect of FA on heart anomalies among DS infants.
Nevertheless, several limitations of the present study
should be considered. Because data about exposure are col-
lected after birth, information bias could occur. We at-
tempted to minimize such bias by using standardized
questionnaires and by conducting the interviews relatively
soon after the infant’s birth. By using other DS affected
infants as controls, we attempted to avoid recall bias, a spe-
ciﬁc type of information bias.
Not all infants with DS encountered in the study hospi-
tals were enrolled in the study because DS was only on the
priority list between 1983 and 1987. In the other years,
many infants with DS were enrolled not because of the spe-
ciﬁc diagnosis of DS, but rather because of the presence of
other malformations. However, there is no reason to
assume that recruitment of subjects was related to use of
FA-containing products, making it unlikely that this pro-
cess introduced selection bias. Another possibility is that
defects that may be FA-sensitive (such as neural tube or
urinary tract defects) were included in the control group.
However, the numbers of such defects among controls
were small, and the proportions of DS affected infants with
these defects did not differ between cases and controls,
suggesting that such bias is unlikely.
Misclassiﬁcation of cases and controls might have oc-
curred if cardiac defects were not identiﬁed or coded.
While such misclassiﬁcation is unlikely to be biased be-
cause it is unlikely to be related to FA exposure, nondiffer-
ential misclassiﬁcation could tend to obscure a protective
effect of FA on heart anomalies.
Finally, residual confounding is still a possible expla-
nation for not ﬁnding a protective effect of FA in this
population. In our multivariate model, we adjusted for
several factors that are associated with either FA use or
cardiac anomalies; nevertheless, other variables might
differ between the women who take FA in early preg-
nancy and women who take no FA during that time. If
these differences are related to the presence of heart de-
fects, confounding could explain our ﬁndings.
The current literature reﬂects discussion about the effect
of FA on the etiology of DS itself. Polymorphisms of the
methylene tetrahydrofolate reductase gene were more prev-
alent among mothers of children with DS than among con-
trol mothers in some studies (Hobbs et al., 2000; James
et al., 1999), though other researchers could not conﬁrm this
difference (Petersen et al., 2000). Furthermore, Czeizel and
Puho (2005) found a decreased risk for DS after periconcep-
tional high-dose FA use in a population-based study. If FA
were to protect against DS itself, perhaps the same phenom-
enon that results in a DS birth despite FA use in pregnancy
would also result in a lack of FA protection against heart
anomalies. Alternatively, a higher dose might be required
Table 1






n % n %
Smokingb
Never 76 41.3 118 52.9
During (part of) pregnancy 67 36.4 48 21.5
Exsmoker 41 22.3 57 25.6
Alcohol during pregnancya
Yes 33 20.2 49 23.7
Missing n ¼ 37
Material raceb
White (vs. non-White) 171 92.9 192 86.1
Material age at conception
<25 32 17.4 37 16.6
25–29 55 29.9 69 30.9
30–34 56 30.4 55 24.7
>34 41 22.3 62 27.8
Maternal years of education
<12 23 12.5 27 12.1
12 53 28.8 63 28.3
13–15 59 32.1 57 25.6
>15 49 26.6 76 34.1
Planned pregnancya
Yes 102 62.6 132 64.7
Missing n ¼ 40
Maternal diabetesa,b
Yes 3 1.6 13 5.9
Missing n ¼ 4
Parity
Primipara 42 22.8 51 22.9
Sex of babyb
Male 124 67.4 105 47.1
Center
Boston 65 35.3 67 30.0
Philadelphia 55 29.9 58 26.0
Toronto 64 34.8 98 43.9
aIf missing data: percentages calculated on available data.
bSigniﬁcant difference between cases and controls (P < .05).
Table 2
Maternal Folic Acid Use in Relation to Cases









Heart anomalies 110/113 0.946 0.608–1.471
Conotruncal
defects 10/10 0.704 0.213–2.323
VSD 40/33 1.456 0.774–2.739
Ostium secundum
type ASD 40/33 0.943 0.481–1.847
Endocardial
cushion defects 42/43 0.766 0.419–1.367
ORs were adjusted for race, age, education, diabetes, year of
birth, center.
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to achieve an effect on heart anomalies in DS. Most multivi-
tamin products contain 400 mg of FA; while that dose may
be sufﬁcient to reduce cardiac anomaly risks in otherwise
normal fetuses, perhaps a larger dose may be needed to
protect against development of a heart anomaly when a
trisomy 21 is already present.
Findings from previous studies that focused on the
effects of certain exogenous maternal factors on the risks
of birth defects in DS have been inconsistent, but maternal
age and race might play a role. In our study, we found no
differences in maternal age between cases and controls.
Our ﬁndings on maternal race are consistent with Khoury
and Erickson (1992) though not with a later study with
more accurate rates of heart anomalies (Freeman et al.,
1998). This is the ﬁrst study to investigate the effect of FA
on heart anomalies among DS children, and it failed to
provide evidence of such an effect. Further studies could
improve our understanding of this possible relation by
taking into consideration the dose and composition of FA-
containing products and possible polymorphisms in folate
pathway genes.
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